Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.

Lui G Franciosi; Zuzana Diamant; Katharine H Banner; Rob Zuiker; Nicoletta Morelli; Ingrid M C Kamerling; Marieke L de Kam; Jacobus Burggraaf; Adam F Cohen; Mario Cazzola; Luigino Calzetta; Dave Singh; Domenico Spina; Michael J A Walker; Clive P Page

doi:10.1016/S2213-2600(13)70187-5

Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.

Lui G Franciosi, Zuzana Diamant, Katharine H Banner, Rob Zuiker, Nicoletta Morelli, Ingrid M C Kamerling, Marieke L de Kam, Jacobus Burggraaf, Adam F Cohen, Mario Cazzola, Luigino Calzetta, Dave Singh, Domenico Spina, Michael J A Walker, Clive P Page

Respiratory Medicine, Allergology, and Palliative Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Many patients with asthma or chronic obstructive pulmonary disease (COPD) routinely receive a combination of an inhaled bronchodilator and anti-inflammatory glucocorticosteroid, but those with severe disease often respond poorly to these classes of drug. We assessed the efficacy and safety of a novel inhaled dual phosphodiesterase 3 (PDE3) and PDE4 inhibitor, RPL554 for its ability to act as a bronchodilator and anti-inflammatory drug.

Original language	English
Pages (from-to)	714-727
Journal	The Lancet Respiratory Medicine
Volume	1
Issue number	9
DOIs	https://doi.org/10.1016/S2213-2600(13)70187-5
Publication status	Published - 2013

Subject classification (UKÄ)

Respiratory Medicine and Allergy

Access to Document

10.1016/S2213-2600(13)70187-5

http://www.ncbi.nlm.nih.gov/pubmed/24429275?dopt=Abstract

Cite this

Franciosi, L. G., Diamant, Z., Banner, K. H., Zuiker, R., Morelli, N., Kamerling, I. M. C., de Kam, M. L., Burggraaf, J., Cohen, A. F., Cazzola, M., Calzetta, L., Singh, D., Spina, D., Walker, M. J. A., & Page, C. P. (2013). Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. The Lancet Respiratory Medicine, 1(9), 714-727. https://doi.org/10.1016/S2213-2600(13)70187-5

@article{33b40e8f608d409784a836f3bd11be2c,

title = "Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.",

abstract = "Many patients with asthma or chronic obstructive pulmonary disease (COPD) routinely receive a combination of an inhaled bronchodilator and anti-inflammatory glucocorticosteroid, but those with severe disease often respond poorly to these classes of drug. We assessed the efficacy and safety of a novel inhaled dual phosphodiesterase 3 (PDE3) and PDE4 inhibitor, RPL554 for its ability to act as a bronchodilator and anti-inflammatory drug.",

author = "Franciosi, {Lui G} and Zuzana Diamant and Banner, {Katharine H} and Rob Zuiker and Nicoletta Morelli and Kamerling, {Ingrid M C} and {de Kam}, {Marieke L} and Jacobus Burggraaf and Cohen, {Adam F} and Mario Cazzola and Luigino Calzetta and Dave Singh and Domenico Spina and Walker, {Michael J A} and Page, {Clive P}",

year = "2013",

doi = "10.1016/S2213-2600(13)70187-5",

language = "English",

volume = "1",

pages = "714--727",

journal = "The Lancet Respiratory Medicine",

issn = "2213-2600",

publisher = "Elsevier",

number = "9",

}

Franciosi, LG, Diamant, Z, Banner, KH, Zuiker, R, Morelli, N, Kamerling, IMC, de Kam, ML, Burggraaf, J, Cohen, AF, Cazzola, M, Calzetta, L, Singh, D, Spina, D, Walker, MJA & Page, CP 2013, 'Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.', The Lancet Respiratory Medicine, vol. 1, no. 9, pp. 714-727. https://doi.org/10.1016/S2213-2600(13)70187-5

Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. / Franciosi, Lui G; Diamant, Zuzana; Banner, Katharine H et al.
In: The Lancet Respiratory Medicine, Vol. 1, No. 9, 2013, p. 714-727.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.

AU - Franciosi, Lui G

AU - Diamant, Zuzana

AU - Banner, Katharine H

AU - Zuiker, Rob

AU - Morelli, Nicoletta

AU - Kamerling, Ingrid M C

AU - de Kam, Marieke L

AU - Burggraaf, Jacobus

AU - Cohen, Adam F

AU - Cazzola, Mario

AU - Calzetta, Luigino

AU - Singh, Dave

AU - Spina, Domenico

AU - Walker, Michael J A

AU - Page, Clive P

PY - 2013

Y1 - 2013

N2 - Many patients with asthma or chronic obstructive pulmonary disease (COPD) routinely receive a combination of an inhaled bronchodilator and anti-inflammatory glucocorticosteroid, but those with severe disease often respond poorly to these classes of drug. We assessed the efficacy and safety of a novel inhaled dual phosphodiesterase 3 (PDE3) and PDE4 inhibitor, RPL554 for its ability to act as a bronchodilator and anti-inflammatory drug.

AB - Many patients with asthma or chronic obstructive pulmonary disease (COPD) routinely receive a combination of an inhaled bronchodilator and anti-inflammatory glucocorticosteroid, but those with severe disease often respond poorly to these classes of drug. We assessed the efficacy and safety of a novel inhaled dual phosphodiesterase 3 (PDE3) and PDE4 inhibitor, RPL554 for its ability to act as a bronchodilator and anti-inflammatory drug.

U2 - 10.1016/S2213-2600(13)70187-5

DO - 10.1016/S2213-2600(13)70187-5

M3 - Article

SN - 2213-2600

VL - 1

SP - 714

EP - 727

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

IS - 9

ER -

Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.

Abstract

Subject classification (UKÄ)

Access to Document

Fingerprint

Cite this